{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:12:02Z","timestamp":1787314322222,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico of Milan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tralokinumab has demonstrated efficacy in the treatment of atopic dermatitis (AD) in clinical trials and real-world settings. However, there are limited data regarding the long-term use of tralokinumab in real-world settings. Here, we report the findings of a multicentre Italian study conducted to address this knowledge gap.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the drug survival and efficacy of tralokinumab for up to 18\u2005months in 471 patients with severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eczema Area and Severity Index (EASI), Pruritus Numerical Rating Scale, Sleep Disturbance NRS, Dermatology Life Quality Index and Atopic Dermatitis Control Tool (ADCT) scores were recorded for up to 18\u2005months in patients with AD treated with tralokinumab. Drug survival was analysed using the Kaplan\u2013Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall drug survival rate was 81.5% at 12\u2005months. A statistically significantly higher rate of drug survival was found in women (P = 0.006, log-rank = 7.49), in patients with no family history of AD (P = 0.02, log-rank = 5.96) and in patients aged \u2265 60\u2005years (P = 0.02; log-rank = 5.6), when considering drug survival due to inefficacy. We found a significant reduction in the clinical scores evaluated, with patients na\u00efve to biologics or Janus kinase inhibitors (JAKi) showing more rapid improvement. In univariate regression analysis, the following characteristics were associated with an increased likelihood of achieving EASI-75 (\u2265 75% improvement in EASI vs. baseline): being a woman [odds ratio (OR) 1.61, 95% confidence interval (CI) 1.03\u20132.53; P = 0.04], having no atopic comorbidities (OR 1.69, 95% CI 1.03\u20132.78; P = 0.04), having no family history of AD (OR 1.67, 95% CI 1.05\u20132.65; P = 0.01) and having received no concomitant systemic treatment in the previous 12\u2005months (OR 22.07, 95% CI 2.80\u2013173.69; P = 0.003). In multivariate analysis, only a lack of concomitant systemic treatment in the previous 12\u2005months remained statistically significant (OR 23.04, 95% CI 2.79\u2013190.05; P = 0.004).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant improvements in clinical scores were found in patients with AD treated with tralokinumab, with patients na\u00efve to biologics or JAKi experiencing more rapid progress.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf062","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T23:30:52Z","timestamp":1738366252000},"page":"1373-1384","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7188-7310","authenticated-orcid":false,"given":"Francesca","family":"Barei","sequence":"first","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pezzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Bruno","family":"Guanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caroppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Belloni Fortina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marco","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Picone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Trave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-8141","authenticated-orcid":false,"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Dall'Olio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Panasiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo\u00a0Valerio","family":"Marzano","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"2025062505021784200_llaf062-B1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"2025062505021784200_llaf062-B2","first-page":"1435","article-title":"Tralokinumab in atopic dermatitis","volume":"19","author":"Wollenberg","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025062505021784200_llaf062-B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"2025062505021784200_llaf062-B4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/imm.13120","article-title":"The IL-13\u2013OVOL1\u2013FLG axis in atopic dermatitis","volume":"158","author":"Furue","year":"2019","journal-title":"Immunology"},{"key":"2025062505021784200_llaf062-B5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2025062505021784200_llaf062-B6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ra1 and IL-13Ra2","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"2025062505021784200_llaf062-B7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/all.16108","article-title":"Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2\u2005years","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"2025062505021784200_llaf062-B8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025062505021784200_llaf062-B9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2025062505021784200_llaf062-B10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025062505021784200_llaf062-B11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"2025062505021784200_llaf062-B12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdcr.2024.01.021","article-title":"A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients","volume":"46","author":"Herman","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2025062505021784200_llaf062-B13","doi-asserted-by":"crossref","first-page":"T618","DOI":"10.1016\/j.ad.2024.04.008","article-title":"Tralokinumab in atopic dermatitis: real-life data from a Spanish tertiary referral center","volume":"115","author":"Dom\u00ednguez-Santana","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"2025062505021784200_llaf062-B14","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/14712598.2023.2292627","article-title":"Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study","volume":"23","author":"Chiricozzi","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025062505021784200_llaf062-B15","doi-asserted-by":"crossref","first-page":"2285243","DOI":"10.1080\/09546634.2023.2285243","article-title":"Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience","volume":"34","author":"Ferrucci","year":"2023","journal-title":"J Dermatolog Treat"},{"issue":"S1","key":"2025062505021784200_llaf062-B16","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1089\/derm.2023.0261","article-title":"Efficacy and safety of tralokinumab in real life: possible predictive rapid response factors","volume":"35","author":"Potestio","year":"2024","journal-title":"Dermatitis"},{"key":"2025062505021784200_llaf062-B17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/1744666X.2023.2283585","article-title":"A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults","volume":"20","author":"Pezzolo","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"2025062505021784200_llaf062-B18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40261-023-01258-7","article-title":"Real-life experience of tralokinumab for the treatment of adult patients with severe atopic dermatitis: a multicentric prospective study","volume":"43","author":"De Greef","year":"2023","journal-title":"Clin Drug Investig"},{"key":"2025062505021784200_llaf062-B19","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.2147\/CCID.S382424","article-title":"Real-world experience with tralokinumab in a patient with recalcitrant atopic dermatitis: a case report","volume":"15","author":"Moennig","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2025062505021784200_llaf062-B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jaad.2022.07.019","article-title":"Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: interim analysis of the ECZTEND open-label extension trial","volume":"87","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025062505021784200_llaf062-B21","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/jdv.19382","article-title":"Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: a multicentre real-world study","volume":"38","author":"Pezzolo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062505021784200_llaf062-B22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","article-title":"Tralokinumab efficacy over 1\u2005year in adults with moderate-to-severe atopic dermatitis: pooled data from two phase III trials","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"2025062505021784200_llaf062-B23","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.anai.2022.07.007","article-title":"Patient-oriented measures for phase 3 studies of tralokinumab for the treatment of atopic dermatitis (ECZTRA 1, 2, and 3)","volume":"129","author":"Simpson","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025062505021784200_llaf062-B24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.18176\/jiaci.0138","article-title":"Atopic dermatitis in adults: a diagnostic challenge","volume":"27","author":"Silvestre Salvador","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025062505021784200_llaf062-B25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.anai.2020.07.026","article-title":"Real-world persistence with dupilumab among adults with atopic dermatitis","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025062505021784200_llaf062-B26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00008390-199610000-00005","article-title":"Survival analysis: the importance of censored observations","volume":"6","author":"Watt","year":"1996","journal-title":"Melanoma Res"},{"key":"2025062505021784200_llaf062-B27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/ajd.14196","article-title":"Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis","volume":"65","author":"Mel\u00e9-Ninot","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2025062505021784200_llaf062-B28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062505021784200_llaf062-B29","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062505021784200_llaf062-B30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yhbeh.2016.11.017","article-title":"Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences","volume":"88","author":"Roved","year":"2017","journal-title":"Horm Behav"},{"key":"2025062505021784200_llaf062-B31","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1084\/jem.20161807","article-title":"Androgen signaling negatively controls group 2 innate lymphoid cells","volume":"214","author":"Laffont","year":"2017","journal-title":"J Exp Med"},{"key":"2025062505021784200_llaf062-B32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2017.00108","article-title":"Estrogen receptor-dependent regulation of dendritic cell development and function","volume":"8","author":"Laffont","year":"2017","journal-title":"Front Immunol"},{"key":"2025062505021784200_llaf062-B33","first-page":"45","article-title":"Sex hormones and gender disparity in immunity and autoimmunity","volume":"1","author":"Ortona","year":"2015","journal-title":"Ital J Gend Specif Med"},{"key":"2025062505021784200_llaf062-B34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/ced\/llae208","article-title":"Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients","volume":"49","author":"Ferrucci","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"2025062505021784200_llaf062-B35","first-page":"e13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Bello G","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025062505021784200_llaf062-B36","doi-asserted-by":"crossref","first-page":"e23214","DOI":"10.1002\/jcla.23214","article-title":"Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis","volume":"34","author":"Hu","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"2025062505021784200_llaf062-B37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.0905-6157.2003.00106.x","article-title":"Does the severity of atopic dermatitis correlate with serum IgE levels?","volume":"15","author":"Laske","year":"2004","journal-title":"Pediatr Allergy Immunol"},{"key":"2025062505021784200_llaf062-B38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/DER.0000000000000034","article-title":"Associations of childhood eczema severity: a US population-based study","volume":"25","author":"Silverberg","year":"2014","journal-title":"Dermatitis"},{"key":"2025062505021784200_llaf062-B39","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1523-1747.2002.00191.x","article-title":"Dichotomic nature of atopic dermatitis reflected by combined analysis of monocyte immunophenotyping and single nucleotide polymorphisms of the interleukin-4\/interleukin-13 receptor gene: the dichotomy of extrinsic and intrinsic atopic dermatitis","volume":"119","author":"Novak","year":"2002","journal-title":"J Invest Dermatol"},{"key":"2025062505021784200_llaf062-B40","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jamadermatol.2022.3014","article-title":"Dupilumab drug survival and associated predictors in patients with moderate to severe atopic dermatitis: long-term results from the daily practice BioDay Registry","volume":"158","author":"Spekhorst","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025062505021784200_llaf062-B41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/14712598.2024.2372367","article-title":"Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents","volume":"24","author":"Mastorino","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"2025062505021784200_llaf062-B42","doi-asserted-by":"crossref","first-page":"2404718","DOI":"10.1080\/09546634.2024.2404718","article-title":"Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors","volume":"35","author":"Barei","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025062505021784200_llaf062-B43","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"2025062505021784200_llaf062-B44","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1111\/jdv.17050","article-title":"De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort","volume":"35","author":"Jaulent","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025062505021784200_llaf062-B45","doi-asserted-by":"crossref","first-page":"2258240","DOI":"10.1080\/09546634.2023.2258240","article-title":"Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis","volume":"34","author":"Balakirski","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2025062505021784200_llaf062-B46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaci.2023.04.009","article-title":"The neglected twin: nummular eczema is a variant of atopic dermatitis with codominant TH2\/TH17 immune response","volume":"152","author":"B\u00f6hner","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf062\/61742380\/llaf062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1373\/61742380\/llaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1373\/61742380\/llaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T05:02:32Z","timestamp":1750827752000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/7\/1373\/7997479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":46,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf062","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,2,3]]}}}